French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).

@article{Bensadoun2006FrenchMP,
  title={French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).},
  author={Ren{\'e} Jean Bensadoun and Karen B{\'e}n{\'e}zery and Olivier Dassonville and Nicolas Charles Magn{\'e} and Gilles Poissonnet and Alain Rama{\"i}oli and Claire Lemanski and St{\'e}phane Bourdin and Jacques Tortochaux and Fr{\'e}d{\'e}ric Peyrade and P. -Y. Marcy and Emmanuel Chamorey and Jacques Vallicioni and Hang Seng and Claude Alzieu and Bernard G{\'e}ry and Pierre Chauvel and Michael A. E. Schneider and Jos{\'e} Marcondes Santini and François Demard and Gilles Calais},
  journal={International journal of radiation oncology, biology, physics},
  year={2006},
  volume={64 4},
  pages={
          983-94
        }
}
BACKGROUND Unresectable carcinomas of the oropharynx and hypopharynx still have a poor long-term prognosis. Following a previous phase II study, this phase III multicenter trial was conducted between November 1997 and March 2002. METHODS Nontreated, strictly unresectable cases were eligible. Twice-daily radiation: two fractions of 1.2 Gy/day, 5 days per week, with no split (D1-->D46). Total tumor doses: 80.4 Gy/46 day (oropharynx), 75.6 Gy/44 day (hypopharynx). Chemotherapy (arm B): Cisplatin… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 55 CITATIONS

FILTER CITATIONS BY YEAR

2006
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 3 Citations per year over the last 3 years

Similar Papers

Loading similar papers…